This website is intended for healthcare professionals only

Trending Topic

Abstract stethoscope integrated with a smartphone screen, representing digital health, telemedicine, and medical technology health care
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and untreated due to inadequate screening, poor awareness and lack of treatment adherence.3 Globally, HTN is undiagnosed in about 46% […]

Search Results

4 Results Found for “atrial hemodynamics”

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
3d render of red blood cells or corpuscle flowing in a blood vessel.
Mark CompleteCompleted
BookmarkBookmarked

After decades of debate, patent foramen ovale (PFO) closure is now a well-established strategy to reduce recurrent stroke in patients aged 18–60 years who have had a PFO-associated stroke.1 Patients who underwent PFO closure continue to have a higher stroke risk ...

Mark CompleteCompleted
BookmarkBookmarked

At ACC26, Dr Mardi Gomberg-Maitland presented results from the CADENCE trial, showing how sotatercept significantly improves pulmonary hemodynamics in HFpEF-associated pulmonary hypertension, offering hope for the first targeted therapy in this high-risk population.

Developed by Touch
Coverage from: ACC Highlights

The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New ...

Developed by Touch
Coverage from: ACC Highlights

Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO ...

Close Popup